Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. New data from phase 3 trials of monoclonal antibodies for patients with recent COVID-19 diagnoses, ...
The U.S. government has stopped its distribution of Eli Lilly’s COVID-19 antibody bamlanivimab alone, saying that the increasing emergence of coronavirus variants has made the treatment ineffective, ...
The combination therapy reduced the risk of hospitalization or death by 70%. Data from a phase 3 trial investigating Lilly’s severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing ...
The expanded authorization was based on data from the phase 2/3 BLAZE-1 trial. The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results